Hi, Bob. Don’t get me started about the New Yorker article. I, too, expected it to be a tipping point and was very disappointed. As everyone knows, I run the peer support site for tapering off psychiatric drugs, SurvivingAntidepressants.org, which was mentioned a couple of times in the article. (The following remarks are about how Laura is represented in the story as a character, not the real Laura Delano, who, as Bob points out, has a somewhat different story.) Reading without benefit of Laura’s backstory (which we know from MIA), I perceive Rachel Aviv’s story as written to be one of psychiatric overdrugging, polypharmacy, and potential misdiagnosis. While numerous psychiatric experts probably associated with Harvard (crux of biological psychiatry) were involved in a long trail of mistreatment, I believe psychiatrists will view Laura’s case as an outlier. The article failed to convey how common psychiatric misdiagnosis, overdrugging, etc. is. It also glossed over how Laura came off the drugs, and since she had also overdosed and suffered from rhabdomyolysis, psychiatrists will attribute the cursory description of her post-withdrawal symptoms to that. So no game-changing there. The general reader may be appalled by the description of prescription cascade, polypharmacy, and adverse effects, but not get the very important point: ANYONE can be taking even one psychiatric drug, have trouble coming off, and meet nothing but misdiagnosis and mistreatment of adverse reactions, particularly withdrawal symptoms. The writer, Rachel Aviv, deliberately misrepresented the topic to me as a long, in-depth article about online peer support for coming off psychiatric drugs. (Beyond my site and Laura’s The Withdrawal Project, which shares much content with my site, there is an extensive peer support network serving hundreds of thousands if not millions of people.) I perceived a New Yorker article about this could be a game-changer for finally handing off psychiatric drug tapering to physicians, where it belongs. Consequently, I spent many hours corresponding with Aviv, sending her dozens of journal articles, in which she seemed very interested. We went back and forth in congenial discussion about deep underlying controversies in psychiatry. She ended up quoting several of my sources. Aviv knows the ground, but produced a rather superficial human interest story not much different from other psychiatric drug horror stories published in the New York Times, the Daily Mail, and elsewhere. I also saw signs of stuff chopped out and awkward transitions. We should all have known better — issues in psychiatry flummoxed Louis Menand, an otherwise excellent writer, in a February, 2010 New Yorker article. Not a tipping point, not a game-changer, just another one-off human interest story, and attenuated, as you point out, by unnecessary cant about the benefits of the drugs. For the Web, the article was originally titled the clickbaity The Challenge of Going off Antidepressants — completely inappropriate, as Laura was taking a basket of psychiatric drugs other than antidepressants — if that tells you anything. After the article was published, I expressed my disappointment to Rachel Aviv, who admitted she is also writing a book. This whole experience has certainly changed my view of the New Yorker’s credibility. PS I am now even more determined to transfer responsibility for getting people off psychiatric drugs to the professional medical community and put myself out of business. I am tweeting as @Altostrata with hashtag #Deprescribing.